コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 (Long-Term Intervention With Pravastatin in Ischemic Disease).
2 nslational modification related to aging and ischemic disease.
3 ttempts to develop alternative therapies for ischemic disease.
4 otential therapeutic target for treatment of ischemic disease.
5 V) outcomes in heart failure (HF) and stable ischemic disease.
6 tion construct for the clinical treatment of ischemic disease.
7 may provide unique approaches for mitigating ischemic disease.
8 r treating hyperpermeability associated with ischemic disease.
9 en implicated in the pathogenesis of retinal ischemic disease.
10 Diabetes is a major risk factor for ischemic disease.
11 ndings into new treatments for patients with ischemic disease.
12 of hypoxia tolerance with relevance to human ischemic disease.
13 vascularizing tissue constructs and treating ischemic disease.
14 ansplantation, an association independent of ischemic disease.
15 ikely owing to the inexorable progression of ischemic disease.
16 s HIF as a potential target for treatment of ischemic disease.
17 el-1 may be a useful tool for the therapy of ischemic disease.
18 glucose (simulated ischemia) as a model for ischemic disease.
19 rcome to advance regenerative approaches for ischemic disease.
20 bution, which may be beneficial for treating ischemic diseases.
21 approach with therapeutic potential to treat ischemic diseases.
22 logical cues, holds great potential to treat ischemic diseases.
23 strategies based on EPC in the treatment of ischemic diseases.
24 ity and inflammatory, neurodegenerative, and ischemic diseases.
25 strategy in diabetic patients with critical ischemic diseases.
26 esis is a promising therapeutic approach for ischemic diseases.
27 ew potential therapeutic target to alleviate ischemic diseases.
28 ) are known to promote neovascularization in ischemic diseases.
29 nipulation of the HIF prolyl hydroxylase for ischemic diseases.
30 ncluding cancer, inflammatory disorders, and ischemic diseases.
31 and clinical evaluation for the treatment of ischemic diseases.
32 inhibitors in retinal vascular occlusive and ischemic diseases.
33 od vessel tone that may affect the course of ischemic diseases.
34 involvement of RTP801 in the pathogenesis of ischemic diseases.
35 genesis represents a promising treatment for ischemic diseases.
36 y be useful in the treatment of inflammatory/ischemic diseases.
37 o innovative nanomedicine products targeting ischemic diseases.
38 a(2+) overload which is associated with many ischemic diseases.
39 specific GPR35 agonists for the treatment of ischemic diseases.
40 centers (68 +/- 12 years of age, 32% female, ischemic disease 39%), 74.3% received CRT-defibrillator
41 an association suggesting that small-vessel ischemic disease, a major contributor to the development
42 rugs, inhibit these deleterious processes in ischemic diseases affecting skeletal muscle, and therefo
43 noncardiac surgery may be a useful marker of ischemic disease and a predictor of 6-month prognosis.
44 l and apparently sporadic brain small vessel ischemic disease and CADASIL-like Caucasian patients fro
45 c stroke, PHACTR1 role in brain small vessel ischemic disease and ischemic stroke most important surv
48 VEGF induces vascular permeability (VP) in ischemic diseases and cancer, leading to many pathophysi
49 dominant cap-binding protein (1% hypoxia or ischemic diseases and cancerous tumors), and where both
50 is system represents a promising therapy for ischemic diseases and could be adapted for treatment of
53 provided an effective strategy for treating ischemic diseases and oxidative stress and could acceler
54 exciting possibilities for the treatment of ischemic disease, and furthermore allows the selective t
55 rhythm, and insignificant valvular or active ischemic disease, and groups were matched for age, gende
58 approximately 280 lower-limb amputations for ischemic disease are performed per million people each y
59 responsible for tissue revascularization in ischemic diseases are induced by the IRES-dependent mech
60 uring exercise has been used as a marker for ischemic disease, arrhythmogenic substrate and the long
61 are promising candidates for cell therapy of ischemic diseases, as less than 10% of patients with an
62 teries is essential for revascularization in ischemic diseases, but this is impaired in diabetes.
63 ery rare coding variants in the small vessel ischemic disease-CADASIL-like cohort (p.Glu198Gln, p.Arg
66 etic resistance (age 74.5 +/- 8.2 years; 75% ischemic disease; ejection fraction 31 +/- 15%) and cont
67 anies many forms of heart disease, including ischemic disease, hypertension, heart failure, and valvu
68 ECP), promotes new vessel formation in acute ischemic disease in mice, likely via paracrine mechanism
69 sceptibility factor influencing small vessel ischemic disease in patients and PcomA recruitment in C5
71 r cells (EPCs) are used for the treatment of ischemic diseases in clinical trials, and circulating EP
73 ts used in the treatment of vasoconstrictive/ischemic diseases including pulmonary artery hypertensio
74 een implicated in the development of various ischemic diseases, including ischemic retinopathies.
75 tress is a pathological hallmark of numerous ischemic diseases, including stroke and myocardial infar
76 [Long-term Intervention with Pravastatin in Ischemic Disease]) individually demonstrated reductions
77 d Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) studies collectively accumulate
80 he biology of Mesp1-CPCs in cell culture and ischemic disease models is an important initial step tow
81 s a potential target for treating anemia and ischemic diseases, motivating the development of inhibit
84 evelopment of therapeutic strategies against ischemic diseases, particularly of the cerebro-cardiovas
85 stigating in a larger cohort of small vessel ischemic disease patients, different ischemic stroke sub
87 ve stress that accompanies acute and chronic ischemic disease perturbs connexon forward trafficking.
88 Acute myocardial infarction (MI) is a severe ischemic disease responsible for heart failure and sudde
90 of proangiogenic cells for the treatment of ischemic diseases.Soluble vascular endothelial growth fa
91 ial for hemostasis, but may also cause acute ischemic disease states such as myocardial infarction or
92 rtance, not only in patients with hypoxic or ischemic disease states, but also in patients with other
94 d Long-term Intervention with Pravastatin in Ischemic Disease study, have indicated that cardiovascul
95 in diabetes is a key process contributing to ischemic diseases such as peripheral arterial disease.
100 eterminant of collateral circulation (CC) in ischemic disease, yet the mechanisms driving CC in adult
101 genesis and can potentially be used to treat ischemic diseases, yet in clinical trials VEGF has not f